Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Industry's perception of presenting pharmacoeconomic models to managed care organizations.

Bridget M Olson1, Edward P Armstrong, Amy J Grizzle

  • 1University of Arizona College of Pharmacy, 1703 East Mabel St., Room 318, PO Box 210207, Tucson, AZ 85721, USA. bridget.olson@pharmacy.arizona.edu

Journal of Managed Care Pharmacy : JMCP
|November 14, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Patient-centric care in myelodysplastic syndromes: A global systematic literature review and gap analysis.

Leukemia research·2024
Same author

Patient Experiences with Clostridioides difficile Infection and Its Treatment: A Systematic Literature Review.

Infectious diseases and therapy·2023
Same author

A systematic review of real-world healthcare resource use and costs of <i>Clostridioides difficile</i> infections.

Antimicrobial stewardship & healthcare epidemiology : ASHE·2023
Same author

Cost of illness of stage IV non-small cell lung cancer (NSCLC) positive for programmed cell death ligand 1 (PD-L1) in the US.

Expert review of pharmacoeconomics & outcomes research·2022
Same author

Cost-effectiveness of herpes zoster vaccines in the U.S.: A systematic review.

Preventive medicine reports·2022
Same author

Cost-Effectiveness of PD-L1 Testing in Non-Small Cell Lung Cancer (NSCLC) Using In Vitro Diagnostic (IVD) Versus Laboratory-Developed Test (LDT).

Oncology and therapy·2022

Pharmacoeconomic (PE) models influence health policy decisions, though no single model type is universally most effective. Improving PE models requires scientific rigor, customization, transparency, user-friendliness, and unbiased development for better utilization.

Area of Science:

  • Health Economics
  • Health Policy Research
  • Pharmaceutical Industry Analysis

Background:

  • Pharmacoeconomic (PE) data is recognized as crucial for decision-making but often underutilized.
  • Limited research exists on comparing the effectiveness of various PE model types.

Purpose of the Study:

  • To assess the perceived value and understanding of PE models among managed care decision-makers.
  • To identify barriers hindering the effective use of PE models.
  • To propose strategies for enhancing PE model development and application.

Main Methods:

  • A telephone survey was administered to 20 research scientists in the pharmaceutical and biotechnology sectors.
  • The survey comprised 39 items covering model reception, usage barriers, and improvement recommendations.

Related Experiment Videos

Main Results:

  • PE models demonstrably impact health policy and formulary positioning.
  • No single PE model format was identified as superior; effectiveness varied.
  • Simple spreadsheet models and complex regression models were both cited as effective.

Conclusions:

  • PE models are actively used and influence health policy decisions in managed care.
  • A consensus on the most effective PE model type is lacking, with diverse designs proving valuable.
  • Recommendations for improvement include scientific soundness, customization, transparency, user-friendliness, and unbiased third-party involvement.